D-Index & Metrics Best Publications

Amit Bar-Or

University of Pennsylvania
United States

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Immunology D-index 83 Citations 26,325 305 World Ranking 900 National Ranking 502

Medicine D-index 99 Citations 37,427 522 World Ranking 5116 National Ranking 2846

Overview

What is he best known for?

The fields of study he is best known for:

Internal medicine
Immune system
Disease

His main research concerns Multiple sclerosis, Immunology, Immune system, Internal medicine and Microglia. A large part of his Multiple sclerosis studies is devoted to Acute disseminated encephalomyelitis. Amit Bar-Or has included themes like Placebo, Surgery and Ocrelizumab in his Internal medicine study.

His studies in Ocrelizumab integrate themes in fields like Hazard ratio and Monoclonal. His Microglia research includes elements of Acquired immune system, Neuroimmunology, Neuroinflammation, Monocyte and Innate immune system. The various areas that Amit Bar-Or examines in his Randomized controlled trial study include Gastroenterology, Teriflunomide and Phases of clinical research.

His most cited work include:

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. (1745 citations)
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis (1137 citations)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis (720 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of investigation include Multiple sclerosis, Immunology, Internal medicine, Immune system and In patient. His work carried out in the field of Multiple sclerosis brings together such families of science as Clinical trial, Disease, Pathology and Central nervous system, Neuroscience. His work in Antibody, T cell, Antigen, Cytokine and B cell are all subfields of Immunology research.

His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology, Placebo, Expanded Disability Status Scale and Ocrelizumab. The concepts of his Placebo study are interwoven with issues in Dimethyl fumarate, Physical therapy and Randomized controlled trial, Surgery. Amit Bar-Or interconnects Inflammation and Cell biology in the investigation of issues within Immune system.

He most often published in these fields:

Multiple sclerosis (61.73%)
Immunology (43.65%)
Internal medicine (26.73%)

What were the highlights of his more recent work (between 2017-2021)?

Multiple sclerosis (61.73%)
Internal medicine (26.73%)
Immunology (43.65%)

In recent papers he was focusing on the following fields of study:

Multiple sclerosis, Internal medicine, Immunology, In patient and Immune system are his primary areas of study. Amit Bar-Or combines subjects such as Ocrelizumab, Clinical trial and Central nervous system, Neuroscience with his study of Multiple sclerosis. In his study, which falls under the umbrella issue of Internal medicine, Dimethyl fumarate is strongly linked to Gastroenterology.

His Immune system research incorporates themes from Flow cytometry, Cytotoxic T cell, Disease and Cell biology. In T cell, Amit Bar-Or works on issues like Cancer research, which are connected to B cell. His Randomized controlled trial research incorporates elements of Placebo and Interferon beta-1a.

Between 2017 and 2021, his most popular works were:

Reassessing B cell contributions in multiple sclerosis (111 citations)
Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. (101 citations)
Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10 (100 citations)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Stephen L. Hauser;Emmanuelle Waubant;Douglas L. Arnold;Timothy Vollmer.
The New England Journal of Medicine (2008)

2450 Citations

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

Ralf Gold;Ludwig Kappos;Douglas L Arnold;Amit Bar-Or.
The New England Journal of Medicine (2012)

1767 Citations

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

Xavier Montalban;Stephen L. Hauser;Ludwig Kappos;Douglas L. Arnold.
The New England Journal of Medicine (2017)

1371 Citations

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Stephen L. Hauser;Amit Bar-Or;Giancarlo Comi;Gavin Giovannoni.
The New England Journal of Medicine (2017)

1263 Citations

IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases

Ping Shen;Toralf Roch;Vicky Lampropoulou;Richard A. O’Connor.
Nature (2014)

934 Citations

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

Ludwig Kappos;David Li;Peter A Calabresi;Paul O'Connor.
The Lancet (2011)

838 Citations

Distinct Effector Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis

Martin Duddy;Masaaki Niino;Femina Adatia;Sherry Hebert.
Journal of Immunology (2007)

673 Citations

B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells

Tom A. Barr;Ping Shen;Sheila Brown;Vicky Lampropoulou.
Journal of Experimental Medicine (2012)

594 Citations

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.

Amit Bar-Or;Peter A. J. Calabresi;Douglas Arnold;Clyde Markowitz.
Annals of Neurology (2008)

543 Citations

Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays

P.J. Waters;A. McKeon;M.I. Leite;S. Rajasekharan.
Neurology (2012)

517 Citations

If you think any of the details on this page are incorrect, let us know.

Frequent Co-Authors

External Links

Personal Website for Amit Bar-Or